NASDAQ:RXRX - Recursion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.20
  • Forecasted Upside: -0.93 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$33.51
▼ -2.2 (-6.16%)

This chart shows the closing price for RXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Recursion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RXRX

Analyst Price Target is $33.20
▼ -0.93% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Recursion Pharmaceuticals in the last 3 months. The average price target is $33.20, with a high forecast of $36.00 and a low forecast of $31.00. The average price target represents a -0.93% upside from the last price of $33.51.

This chart shows the closing price for RXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Recursion Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021SVB LeerinkInitiated CoverageOutperform$33.00High
5/11/2021JPMorgan Chase & Co.Initiated CoverageNeutral$32.00High
5/11/2021The Goldman Sachs GroupInitiated CoverageNeutral$34.00High
5/11/2021Bank of AmericaInitiated CoverageBuy$31.00High
5/11/2021KeyCorpInitiated CoverageOverweight$36.00High
(Data available from 6/23/2016 forward)
Recursion Pharmaceuticals logo
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Read More

Today's Range

Now: $33.51
Low: $33.21
High: $36.80

50 Day Range

MA: $28.58
Low: $21.06
High: $37.42

52 Week Range

Now: $33.51
Low: $19.68
High: $37.85

Volume

307,091 shs

Average Volume

478,502 shs

Market Capitalization

$5.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Recursion Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Recursion Pharmaceuticals in the last year: Bank of America Co., JPMorgan Chase & Co., KeyCorp, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RXRX.

What is the current price target for Recursion Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Recursion Pharmaceuticals in the last year. Their average twelve-month price target is $33.20, suggesting a possible downside of 0.9%. KeyCorp has the highest price target set, predicting RXRX will reach $36.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $31.00 for Recursion Pharmaceuticals in the next year.
View the latest price targets for RXRX.

What is the current consensus analyst rating for Recursion Pharmaceuticals?

Recursion Pharmaceuticals currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RXRX will outperform the market and that investors should add to their positions of Recursion Pharmaceuticals.
View the latest ratings for RXRX.

What other companies compete with Recursion Pharmaceuticals?

How do I contact Recursion Pharmaceuticals' investor relations team?

Recursion Pharmaceuticals' physical mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The company's listed phone number is 385 269 0203 and its investor relations email address is [email protected] The official website for Recursion Pharmaceuticals is www.recursion.com.